Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Analyst Reports for Mastercard, UnitedHealth & Merck

Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), UnitedHealth Group (UNH) and Merck (MRK).

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks

The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

Dr. Reddy's (RDY) Q2 Earnings and Revenues Increase Y/Y

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2020.

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) beats earnings estimates but misses sales estimates in the third quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.

Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss

The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.

Exelixis (EXEL) Q3 Earnings Beat on Strong Cabometyx Sales

Exelixis (EXEL) reports solid third-quarter 2019 results as Cabometyx maintains momentum.

Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

Stock Market News For Oct 30, 2019

Benchmarks closed in the negative territory on Tuesday due to Alphabet???s weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.

Sweta Killa headshot

Healthcare ETFs Win in October: Here's Why

The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q3 Earnings?

Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

Strong Q3 Earnings Data Deluge

Strong Q3 Earnings Data Deluge

Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View

Merck (MRK) beats estimates for earnings as well as sales in third-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.

Mark Vickery headshot

Q3 Earnings Bonanza: GM, MRK, MA & More

GM fought through strike headwinds to beat estimates, Merck's cancer drug performs great, and Pfizer and Mastercard beat, too.

Merck (MRK) Q3 Earnings and Revenues Surpass Estimates (Revised)

Merck (MRK) delivered earnings and revenue surprises of 20.80% and 5.96%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Tops Q3 Earnings Estimates

Merck (MRK) delivered earnings and revenue surprises of 20.80% and -99.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.

Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.

Why Earnings Season Could Be Great for Merck (MRK)

Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Value Trader Highlights: Merck, Disney, Whitestone REIT, Gap and Wells Fargo

Zacks Value Trader Highlights: Merck, Disney, Whitestone REIT, Gap and Wells Fargo

Tracey Ryniec headshot

Lessons on How to Build a Million Dollar Portfolio

Anne Scheiber started with $5,000 and in the end her portfolio was worth $22 million. Here???s how she did it.